A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Gritstone bio, Inc.
- Study ID
- NCT03953235
- Phase
- PHASE1/PHASE2
- Status
- Completed
Conditions
- Colorectal Cancer
- Non-Small Cell Lung Cancer
- Pancreatic Cancer
- Shared Neoantigen-Positive Solid Tumors
- Solid Tumor
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- GRT-C903 — BIOLOGICALa shared neoantigen cancer vaccine prime
- GRT-R904 — BIOLOGICALa shared neoantigen cancer vaccine boost
- nivolumab — BIOLOGICALanti-PD-1 monoclonal antibody
- ipilimumab — BIOLOGICALanti-CTLA-4 monoclonal antibody
Study Details
The purpose of this study is to evaluate the dose, safety, immunogenicity and early clinical activity of GRT-C903 and GRT-R904, a neoantigen-based therapeutic cancer vaccine, in combination with immune checkpoint blockade, in patients with advanced or metastatic non-small cell lung cancer, microsatellite stable colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. Based on the Phase 1 data, an updated vaccine candidate (SLATE-KRAS or version 2) was developed that removed 16 of the 20 mutations included in the original vaccine (version 1) and solely targets KRAS mutations.
Key Dates
- Start date
- Jul 18, 2019
- Status verified
- Sep 2023
- Primary completion
- Mar 10, 2023
- Completion
- Mar 10, 2023
Study Design
- Enrollment
- 39 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Phase 1* GRT-C903 * GRT-R904 * nivolumab * ipilimumab
- Experimental: Phase 2* GRT-C903 * GRT-R904 * nivolumab * ipilimumab Phase 2 for some patients includes a monthly or every two month treatment schedule
Primary Outcome Measure
Incidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs) [ Time Frame: Initiation of study treatment through 100 days post-last dose (up to approximately 27 months) ]
Locations (12)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic Arizona | Phoenix | Arizona | 85054 | - |
| UCLA Medical Center | Santa Monica | California | 90404 | - |
| Mayo Clinic Florida | Jacksonville | Florida | 32224 | - |
| University of Chicago Medicine, Comprehensive Cancer Center | Chicago | Illinois | 60637 | - |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | - |
| Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center | New York | New York | 10032 | - |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | - |
| The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | - |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | - |
| Tennessee Oncology | Nashville | Tennessee | 37203 | - |
| MD Anderson Cancer Center | Houston | Texas | 77030 | - |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | - |
Find similar trials in Phoenix, AZ
Related Studies
- Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic DisordersRecruiting · Mayo Clinic · Phoenix, Arizona
- Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer PatientsRecruiting · Vanderbilt University Medical Center · Nashville, Tennessee
- Pancreatic Adenocarcinoma Gene Environment Risk StudyRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic DiseaseRecruiting · Columbia University · New York, New York